0000000000167202

AUTHOR

Ferraro Donatella

showing 2 related works from this author

Endemic hepatitis C virus infection in a Sicilian town: Further evidence for iatrogenic transmission

2002

The prevalence of and risk factors for HCV and HBV infections in the general population and the predictive value of ALT screening in identifying anti-HCV positive subjects have been evaluated in a small Sicilian town. A random 1:4 sampling from the census of the general population was performed. Anti-HCV, HCV-RNA, HCV genotype, HBsAg, and anti-HBc were tested. The linkage between HCV infection and potential risk factors was evaluated by multiple logistic regression analysis. Among 721 subjects studied, 75 (10.4%) were anti-HCV positive. The HCV infection rate increased from 0.4% in subjects 10-29 years of age to 34% in those > 60 years of age. Among the 75 anti-HCV positive subjects, 66.7% …

AdultMaleEndemic DiseasesAdolescentEpidemiologyIatrogenic DiseasePredictive Value of TestEndemic DiseaseHepacivirusAge DistributionPredictive Value of TestsRisk FactorsVirologyPrevalenceHumansChildSicilyAgedAged 80 and overHepaciviruRisk FactorGeneral populationAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesMiddle AgedHepatitis BHepatitis CPopulation SurveillanceFemaleHepatitis C viruHepatitis C AntibodieHuman
researchProduct

Hepatitis B virus reactivation and alemtuzumab therapy

2005

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occult HBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab the…

MaleSettore MED/07 - Microbiologia E Microbiologia ClinicaHepatitis B virusHBsAgCD52Antibodies Neoplasmmedicine.medical_treatmenthepatitis B viruAntibodies Monoclonal Humanizedmedicine.disease_causeCampath-1HSettore MED/15 - Malattie Del SanguemedicineHumansAlemtuzumabImmunosuppression TherapyHepatitisHepatitis B virusSettore MED/12 - GastroenterologiaHepatitis B Surface Antigensbusiness.industryacute hepatitiAntibodies Monoclonalvirus diseasesLamivudineImmunosuppressionHematologyGeneral MedicineMiddle AgedHepatitis BHepatitis Bmedicine.diseaseLeukemia Lymphocytic Chronic B-Celldigestive system diseasesLamivudineDNA ViralImmunologyReverse Transcriptase InhibitorsAlemtuzumabFemaleVirus Activationbusinesschronic lymphocytic leukaemiamedicine.drugEuropean Journal of Haematology
researchProduct